Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Fady Malik sold 3,500 shares of the company’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $51.78, for a total value of $181,230.00. Following the transaction, the executive vice president owned 153,902 shares of the company’s stock, valued at approximately $7,969,045.56. The trade was a 2.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

  • On Tuesday, November 3rd, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $62.93, for a total value of $220,255.00.
  • On Tuesday, October 20th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $64.01, for a total transaction of $224,035.00.
  • On Tuesday, October 6th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $61.38, for a total transaction of $214,830.00.
  • On Tuesday, September 22nd, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $68.29, for a total transaction of $239,015.00.
  • On Tuesday, September 8th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $75.46, for a total transaction of $264,110.00.

Cytokinetics Trading Down 0.6%

Shares of NASDAQ:CYTK opened at $51.32 on Thursday. The firm’s 50 day moving average is $62.79 and its two-hundred day moving average is $69.60. Cytokinetics, Incorporated has a 52 week low of $51.00 and a 52 week high of $88.31. The firm has a market capitalization of $7.15 billion, a P/E ratio of -8.50 and a beta of 0.45.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.06. The business had revenue of $47.56 million for the quarter, compared to the consensus estimate of $41.88 million. The business’s quarterly revenue was up 2356.5% on a year-over-year basis. During the same period last year, the firm posted ($2.55) EPS. Analysts predict that Cytokinetics, Incorporated will post -5.85 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allworth Financial LP raised its position in Cytokinetics by 214.3% in the third quarter. Allworth Financial LP now owns 1,697 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 1,157 shares in the last quarter. Quarry LP lifted its holdings in Cytokinetics by 295.9% in the 3rd quarter. Quarry LP now owns 16,064 shares of the biopharmaceutical company’s stock valued at $1,059,000 after acquiring an additional 12,006 shares during the last quarter. Readystate Asset Management LP bought a new position in shares of Cytokinetics during the 3rd quarter valued at about $10,722,000. Bellevue Group AG boosted its position in shares of Cytokinetics by 64.8% during the 3rd quarter. Bellevue Group AG now owns 31,324 shares of the biopharmaceutical company’s stock valued at $2,065,000 after purchasing an additional 12,317 shares in the last quarter. Finally, CSM Advisors LLC boosted its position in shares of Cytokinetics by 62.6% during the 3rd quarter. CSM Advisors LLC now owns 29,406 shares of the biopharmaceutical company’s stock valued at $1,939,000 after purchasing an additional 11,320 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently commented on CYTK. Citizens Jmp raised their target price on Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Barclays boosted their price target on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Morgan Stanley raised Cytokinetics from an “overweight” rating to a “buy” rating in a research note on Tuesday, September 1st. Royal Bank Of Canada raised their price target on Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Finally, Needham & Company LLC raised their price target on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $106.67.

Get Our Latest Analysis on Cytokinetics

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Read More

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.